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A r t i c l e s
The development of functional adaptive immunity is driven by a series of rearrangements in genomic DNA in lymphocytes that are required for the generation of antigen-recognition diversity, receptor editing and lymphoid effector function 1 . In mature, naive B lymphocytes, immunoglobulin class-switch recombination is initiated by activation-induced cytidine deaminase (AID) 2 . Mutations in the gene encoding AID (AICDA) lead to immunoglobulin class switching and somatic hypermutation defects in mice and humans and underlie human hyper-immunoglobulin M (IgM) syndrome 3 . In the immunoglobulin heavy-chain (Igh) locus, AID-dependent DNA double-strand breaks (DSBs) occur mainly in transcribed, repetitive sequences called switch (S) regions, upstream of isotypespecific coding exons. Unlike the site-specific activity of the RAG recombination-activating molecules, AID activity is independent of the target sequence 4 . In this context, two studies have found evidence that AID can induce rare point mutations or DSBs, respectively, in select non-immunoglobulin genes 5, 6 . These findings have spurred efforts to identify off-target AID activity and other putative nonimmunoglobulin AID targets.
It has been reported that AID has off-target point-mutation activity in stimulated B cells 5, 7 . Moreover, the identification of chromosomal translocation breakpoints in or near Igh S regions in some B lymphoid cancers has suggested that AID could potentially stimulate ectopic chromosomal rearrangements, leading to oncogene activation 8 . Consistent with that idea, it was has been found that AID can generate potentially oncogenic DSBs at the Myc protooncogene locus, albeit very rarely and at a substantially lower rate than class-switch recombination-initiating DSBs in Igh S regions 6 .
These off-target AID-induced point mutations and rare translocations have been collectively called 'collateral damage' 9 .
Homologous recombination is a high-fidelity DNA DSB-repair pathway important for maintaining general genome stability in many eukaryotic cells. XRCC2 is a key member of the RAD51 family of mammalian homologous-recombination factors [10] [11] [12] . XRCC2-deficient cells show proliferation defects, hypersensitivity to ionizing radiation and other DNA-damaging agents, and spontaneous chromosomal instability [12] [13] [14] . Mice with homozygous deletion of Xrcc2 die during mid-gestation, associated with widespread cellular apoptosis 12, 15, 16 . XRCC2 is required for successful proliferation and genomic integrity in early developing B cells 17 . Here we have investigated the interaction between AID and XRCC2 in mature, activated B cells. We found that AID promiscuously attacked the genome, leading to widespread, highly cytotoxic DSBs in activated, XRCC2-defective mature B cells. Our findings emphasize homologous recombination as a critical genome-protective pathway in activated B cells that is important for resistance to the potentially deleterious effects of the off-target activity of AID.
RESULTS

Activation is toxic to XRCC2-defective B cells
We initially found that XRCC2, like its paralog RAD51, was transcriptionally upregulated after B cell activation 18 ( Supplementary  Fig. 1a-b) . To investigate the interrelationship among B cell activation, immunoglobulin class switching and XRCC2, we next tested whether Xrcc2-deficient B cells had impaired immunoglobulin class switching. Because being null for Xrcc2 results in embryonic death in A r t i c l e s mice 12, 14, 16 , we used a fetal liver cell culture system to obtain Xrcc2-null primary B cells 17, 19 (Supplementary Fig. 2) . We transferred the resulting mature, naive, IgM-expressing B cells to medium containing either antibody to CD40 (anti-CD40) alone (nonactivated), to induce proliferation without class switching, or anti-CD40 plus interleukin 4 (IL-4; activated), to induce proliferation and class-switch recombination (Fig. 1a,b and Supplementary Figs. 3 and 4) . After 3 d of activation, control (Xrcc2 +/+ ) cultures showed efficient isotype switching from IgM to IgG1 (Fig. 1a-b and Supplementary  Fig. 4 ). In contrast, activated Xrcc2-deficient cultures were severely compromised in class switching, showing no increase in the number of IgG1 + cells after activation (Fig. 1b) . Notably, we also observed a smaller fraction of IgM + B cells in activated Xrcc2-null cultures but not in Xrcc2 +/+ cultures ( Fig. 1a and Supplementary Fig. 4) . Even a partial decrease in XRCC2 function conferred activation-dependent cytotoxicity. Using a lentivirus-based system to deliver constructs of Xrcc2-specific short hairpin RNA (shRNA; resulting in XKD cells) or scrambled control shRNA to primary splenic B cells or B cell lines ( Fig. 1c and Supplementary Fig. 5-9 ), we found that knockdown of XRCC2, like being null for Xrcc2, sensitized B cells to activation (Fig. 1c) . Deficiency in the tumor suppressor p53 (encoded by Trp53) can restore early B cell development in an Xrcc2-mutant fetal liver culture assay 17 . Here, using the lentivirus-based shRNA system, we were able to demonstrate partial restoration of B cells in the absence of p53, which indicated that there may be p53-dependent and p53-independent responses to activation in mature B cells.
AID-dependent activation-induced B cell cytotoxicity
Because XRCC2-defective B cells (Xrcc2-deficient cells and XKD cells) were sensitive to activation, we hypothesized that cytotoxicity might be mediated by AID. To test this, we did stimulation and survival assays in XKD cells derived from either normal (Aicda +/+ ) mice or AID-deficient (Aicda −/− ) mice (Fig. 1d-f and Supplementary Fig. 8) . Consistent with the results reported above, knockdown of XRCC2 in Aicda +/+ B cells compromised survival after activation (Fig. 1d-f) . In contrast, activation of XKD B cells from Aicda −/− mice produced no detectable change in viability or survival relative to lack of activation. To further verify that activation directly induced AID-dependent B cell cytotoxicity, we repeated the survival assays using starting cell populations enriched specifically for IgM + B cells and assayed at various time points after activation ( Fig. 1e-f) . Whereas purified normal or Trp53 −/− XKD B cells showed activation-induced cytotoxicity, purified Aidca −/− XKD B cells were resistant to the deleterious effects of activation (Fig. 1e-f) . Together with the data above, these results demonstrate that AID induces substantial cellular toxicity in activated, homologous recombination-defective primary B cells.
AID induces widespread genomic breaks in B cells
Because XRCC2 has well-known DSB repair functions 20 , we next sought to determine whether AID-induced toxicity was associated with unrepaired DSBs in Xrcc2-defective B cells. To test this prediction, we supplemented Aicda +/+ or Aicda −/− XKD B cell cultures with either anti-CD40 alone (nonactivated) or anti-CD40 plus IL-4 (activated) and then stained the cells for foci of γ-H2AX, a marker of unrepaired DSBs 21 (Fig. 2a) . Both control and XKD B cell cultures showed an AID-dependent larger fraction of γ-H2AX + cells (cells containing one γ-H2AX focus or more γ-H2AX foci) after activation (Fig. 2b) . As expected, Aicda −/− cultures transduced with control shRNA or Aicda −/− XKD cultures showed no change in γ-H2AX positivity after activation (Fig. 2b) . However, when we quantified foci per cell in the γ-H2AX + fraction, we found that XKD cells had specific and significant increase in the number of γ-H2AX foci per cell (from approximately two foci per cell before activation to more than four foci per cell after activation; Fig. 2c) . Notably, this effect was abrogated in Aicda −/− cells and thus we conclude that it was dependent on AID (Fig. 2c) . We next quantified the fraction of γ-H2AX + cells that specifically contained supernumerary (more than two) γ-H2AX foci, reasoning that such foci might represent potential off-target, non-immunoglobulin DSBs. Consistent with our prediction, 
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we observed a significantly greater fraction of XKD cells that contained AID-dependent, supernumerary γ-H2AX foci ( Fig. 2d) , which supported the possibility of AID-related DSBs at genomic locations other than the two copies of the Igh locus. Finally, further analysis of the distribution of foci showed a substantial shift toward more foci per cell in activated Aicda +/+ XKD cultures but not in activated Aicda −/− XKD cultures (Fig. 2e,f) . Critically, this effect was not due to differences in cell-cycle responses to anti-CD40 versus anti-CD40 plus IL-4, as both culture conditions elicited similar overall cell-cycle profiles ( Supplementary Fig. 3 ). We also observed a similar γ-H2AX response in the class-switch-competent mouse B cell line CH12-F3 (ref. 22 ) containing the same Xrcc2-knockdown construct used in primary cells (CH12-XKD cells; Supplementary Figs. 7, 9 and 10). Finally, in independent assays we also observed accumulation of activation-induced foci of the DNA damage-response factor 53BP1, another marker of DNA DSBs, specifically in XKD cells but not in control cells (Supplementary Fig. 11 ).
The substantially greater number of DNA-damage foci in activated XRCC2-defective cells suggested AID off-target activity outside the Igh locus. To directly evaluate whether activation-induced DSBs occurred at genomic locations outside Igh, we did fluorescence in situ hybridization (FISH)-immunofluorescence analysis to simultaneously locate Igh loci and γ-H2AX foci. We stained activated and nonactivated CH12-XKD cells with a FISH probe overlapping the 3′ end of the Igh locus (containing Igh constant-region exons with AID-targeted switch regions) and with anti-γ-H2AX ( Fig. 3 and Supplementary Figs. 12 and 13 ). This analysis confirmed that supernumerary foci in activated XKD cells occurred at locations outside and often distant from Igh. Quantification of supernumerary foci showed many more non-immunoglobulin foci per cell and a greater fraction of cells with supernumerary foci in activated XKD cultures ( Fig. 3c-d) . Together these data show that AID can induce a large amount of off-target DNA DSBs at non-immunoglobulin locations in an XRCC2-mutant context.
AID induces S-phase accumulation
Because a role has been demonstrated for XRCC2 in S-phase transit in early B cells 17 , we also measured cell-cycle responses in XRCC2-defective mature B cells. We cultured Aicda +/+ and Aicda −/− XKD B cells, as well as Aicda +/+ and Aicda −/− B cells transduced with a control construct encoding enhanced green fluorescent protein (eGFP), under activating conditions (anti-CD40 plus IL-4) or nonactivating conditions (anti-CD40 alone) and analyzed cell-cycle distribution by quantitative immunofluorescence microscopy assay. We fixed and stained cells from each culture and assessed proliferating cell nuclear antigen (PCNA), a marker of S phase, and phosphorylated histone H3, a marker of mitosis (Fig. 4a,b) . This analysis showed a much greater fraction of cells in the S phase of the cell cycle and a correspondingly smaller M-phase fraction specifically for activated XKD cells (Fig. 4b) . Moreover, we observed this effect only for Aicda +/+ B cells, not for identically treated Aicda −/− B cells (Fig. 4b) , which indicated that the cell-cycle response was directly due to AID activity. We also observed an activation-induced S-phase delay for CH12-XKD cells but not for CH12-F3 cells transduced with control (eGFP) shRNA (Fig. 4c-e and Supplementary Fig. 14) . We next evaluated whether cytotoxicity or AID-dependent offtarget DSBs were associated with apoptotic induction by using several different measures of apoptosis. First we analyzed activated and nonactivated primary XKD cells from wild-type and Trp53 −/− mice for the presence of activated caspase-3 (AC3), a marker of early apoptosis, by immunofluorescence imaging and quantitative flow cytometry (Fig. 5a,b) . As controls for baseline and DNA damage-induced AC3, 
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we measured signals in primary splenocytes before and after exposure to 5 Gy of ionizing radiation, respectively (Fig. 5b) . Consistent with published accounts of activation-mediated B cell apoptosis, we found more AC3 + cells among activated cells transduced with a control (scrambled) shRNA construct (Fig. 5b) . In contrast, the AC3 + fraction was indistinguishable in activated and nonactivated XKD cells from either wild-type or Trp53 −/− mice (Fig. 5b) . To independently analyze apoptosis, we measured genomic DNA laddering (an indicator of late-stage apoptosis) in primary XKD cells and control cells on a wild-type, Trp53 −/− or Aicda −/− genetic background. As observed with AC3 staining, exposure to 5 Gy of ionizing radiation led to detectable DNA laddering and the production of low-molecular-weight DNA in wild-type and Aicda −/− cells but not in apoptosis-resistant Trp53 −/− cells (Fig. 5c, lanes 1 and 2) . In contrast, activation of XKD cells did not produce DNA laddering or a substantial increase in low-molecularweight DNA in either wild-type or Aicda −/− cells (Fig. 5c, lanes 3 and 4) . Knockdown of Xrcc2 did result in the generation of electrophoretically mobile DNA fragments in Trp53 −/− mice, but this was not specific to activation (Fig. 5c , lanes 3 and 4 versus lanes 5 and 6). Together these results indicate that activation-induced DSBs in homologous recombination-defective B cells are directly mediated by AID off-target activity, which leads to S-phase delay and/or arrest but not apoptosis.
AID off-target activity produces chromosomal instability
One implication of the findings reported above is that an off-target assault by AID on the genome might confer a risk of chromosomal instability, with potentially oncogenic consequences. Indeed, one study has suggested that AID can stimulate translocations between Igh and the Myc proto-oncogene 6 . Thus, we tested whether XRCC2 functions to suppress activation-induced chromosomal aberrations in B cells. CH12-XKD cultures showed more chromosome damage than did cultures of CH12-F3 cells transduced with control shRNA, even under nonactivating conditions: 29% of untreated XKD cells and 29%
of nonactivated XKD cells contained chromosomal damage, compared with 13% of untreated control cells and 9% of nonactivated control cells ( Fig. 6 and Table 1 ). However, after activation, 79% of CH12-XKD cells contained chromosomal and chromatid damage, with some cells showing evidence of extreme genome damage. In contrast, 21% of activated CH12-F3 cells transduced with control shRNA contained chromosome breaks or fragments (Fig. 6 , Table 1 and Supplementary  Fig. 15 ). These data demonstrate that B cell activation can induce (sometimes extreme) chromosomal instability and indicate a key role for XRCC2 in suppressing spontaneous and especially activationinduced chromosomal damage in B lymphocytes. Together these findings support a model in which AID promiscuously and broadly attacks the B cell genome, leading to widespread DSBs, a model called 'collateral damage' (Supplementary Fig. 16 ). The homologousrecombination pathway of DSB repair is needed to prevent collateral damage-induced genomic instability or B cell cytotoxicity.
Region 7q36 is linked to genome instability in B cell cancers
In humans, XRCC2 is located on cytoband q36 of chromosome 7 (7q36; ref. 23 ), a region frequently rearranged in various cancers [24] [25] [26] ( Supplementary Fig. 17 ). Our data suggested that XRCC2 might be particularly important for the suppression of activation-induced genomic instability in B cells. To test this, we obtained human B cell-derived lines (Coriell Institute) that contained either intact or cytogenetically aberrant 7q36. The 7q36-aberrant line had expression of XRCC2 approximately 30% that of its 7q36-intact counterpart, but they had similar overall cell cycle and proliferation phenotypes (Fig. 7a-c) . Consistent with its lower XRCC2 expression, the 7q36-aberrant line also showed greater sensitivity to ionizing radiation at all doses tested over a range from 0 Gy to 10 Gy (Fig. 7d) . This is consistent with the idea that 7q36 aberrations can functionally impair XRCC2. Next, to evaluate whether 7q36 aberrations might associate with high chromosome instability in B cell cancers, we analyzed karyotype data from 46,075 case reports in the Mitelman Database of Chromosome Aberrations and Gene Fusions in Cancer. We subcategorized individual cases and compared case reports of all B cell cancers with those of all non-B cell cancers with or without deletions affecting 7q36 (Fig. 7e,f) . We found that deletion of 7q36 was significantly associated with more overall karyotypic instability in both B cell tumors and non-B cell tumors but that the effect was especially strong in the B lineage neoplasms (Fig. 7e,f) . This is consistent with the idea that XRCC2 has a general role in DNA repair and genome stability and that spontaneous chromosomal instability Karyotypes of CH12-F3 cells transduced with control shRNA (CH12-Ctrl) and CH12-XKD cells left untreated (no culture supplement) or cultured under nonactivating conditions (anti-CD40) or activating conditions (anti-CD40 plus IL-4 plus TGF-β).
associated with 7q36 aberrations might be exacerbated in B cell neoplasms. We propose that AID off-target activity might potentially be one source of genome destabilization in B cell cancers with 7q36 aberrations. In this context, AID expression has been shown to be correlated with blast crisis B lineage leukemia and therapy resistance in myeloid leukemia and to be associated with generally poor prognosis in chronic B lymphocytic leukemia 26, 27 . Our data now suggest that synergy between AID action and 7q36 defects might be especially deleterious in patients with such tumors.
DISCUSSION
Here we have investigated the interaction between AID activity and DNA DSB repair in activated B cells. We have demonstrated that in addition to its class-switching and somatic-hypermutation activities, AID also generated a large amount of off-target DSBs in activated B cells, which endangered the B cell genome when DNA break repair was compromised. It will be of interest to identify non-immunoglobulin genomic locations targeted for AID attack. One study has shown that AID can induce rare off-target point mutations at specific non-immunoglobulin genes 5 . Thus, it is possible that these same non-immunoglobulin targets are also subject to AID-induced DSBs. This model would predict that off-target breakage at specific non-immunoglobulin genes should occur during the G1 phase of the cell cycle, when AID is thought to also act on the Igh locus. However, this model might also predict p53-dependent activation of the G1-to S-phase checkpoint in response to off-target DSBs. However, we observed a small overall effect of p53 on AID-induced collateral damage. Therefore, we propose an alternative model in which that DNA replication forks represent likely off-target substrates for inappropriate AID activity. Replication forks contain abundant single-stranded DNA, a known AID substrate, and replication protein A, a known AID cofactor 27 . In this context, AID-dependent cytidine deamination of single-stranded DNA at replication forks could create single-stranded nicks that induce fork collapse and ultimately DSBs, which would be natural substrates for restart of homologous recombination-mediated replication, as has been shown in other contexts 28, 29 .
At many stages of their development, B cells must undergo programmed, DSB-stimulated gene rearrangements: variable-diversityjoining recombination and immunoglobulin class-switch recombination. To successfully complete their developmental program, B cells must properly repair these DSBs and must proliferate [30] [31] [32] . These developmental dynamics in the B cell genome pose the risk of genomic instability.
Although nonhomologous end joining and alternative end joining are known to function in the resolution of programmed DSBs, the pathways that safeguard the genome at large are less well understood 32 . A role for homologous recombination in proliferation and genome stability in early B cell development has been reported 17 . Here we have demonstrated a specific role for the homologous-recombination factor XRCC2 in genome protection in mature B cells in which AID has been activated. In this context, we propose that homologous recombination is essential for resistance to the genome-destabilizing effects of AID-induced collateral damage and is thus essential for the promotion of B cell development. Notably, we have shown that even partially lower XRCC2 expression was sufficient to confer extreme sensitivity to AID off-target damage and cytotoxicity. Polymorphic variants of human XRCC2 have been identified that might be associated with moderately lower XRCC2 function 33 . Our data now suggest that B cells in such people might be more prone to AID off-target damage, which might potentially lead to B cell developmental deficiencies or a greater risk of lymphoid cancer.
The functions of XRCC2 in early B cell development seem to differ from its roles in mature, activated B cells. XRCC2 is proposed to act together with p53 to ensure the integrity of DNA replication forks, or to restart stalled forks, in rapidly proliferating pro-B cells or pre-B cells. In the absence of XRCC2, p53 enforces prolonged early S-phase arrest in developmentally immature B cells. However, ablation of p53 permits XRCC2-null B-precursor cells to transit S phase and complete development, albeit at the cost of high genomic instability. In contrast, the sensitivity of XRCC2-null mature B cells to activation is largely p53 independent. The survival of B cells doubly null for XRCC2 and p53 was severely compromised after activation, which indicated that the genotoxicity was not mediated exclusively by pathways downstream of p53. Notably, in the knockdown experiments, in which the amount of XRCC2 was lower but it was not eliminated, inactivation of p53 led to partial restoration of viability after stimulation. Therefore, we suggest that XRCC2 has a dual role in activated B cells: p53-independent suppression of collateral damage and p53-dependent support of DNA replication. In this context, we also observed an S-phase cell cycle delay in stimulated CH12-XKD cells. This could reflect a replication defect in the absence of XRCC2 or might indicate the involvement of p53-independent checkpoints, such as the DNA damage-sensing and checkpoint-regulating protein ATR, in the response to collateral damage.
In summary, we have shown that AID can promiscuously attack the B cell genome, producing widespread DSBs called 'collateral damage' 9 . We have further demonstrated that the homologous-recombination factor XRCC2 is critical in the resistance to AID-induced collateral damage, ensuring B cell viability and genome stability. Our findings suggest that homologous recombination has coevolved with the adaptive immune system to provide a genomic safeguard against DNAdamaging mechanisms that have been coopted for programmed genome rearrangements in lymphocytes. In this context, we note that chicken B cells undergo AID-induced immunoglobulin diversification by an XRCC2-dependent gene-conversion mechanism. In the absence of XRCC2, chicken B cells resort to a mammalian-like somatic hypermutation mechanism 34 . One possibility is that off-target AID-induced DNA breakage represents a vestigial antigen receptor-diversification process that occurs when homologous recombination-mediated repair is defective. Alternatively, it is possible that AID-initiated gene conversion in avian lymphocytes represents a mode of immunoglobulin rearrangement that is more mechanistically distinct from mammalian somatic hypermutation and class-switch recombination than previously thought. Our data may also provide a molecular explanation for the finding that AID can control germinal center size by inducing B cell apoptosis 35 . AID induces off-target damage, whose extent is controlled by XRCC2-mediated repair. However, a fraction of cells with off-target damage might evade XRCC2-mediated repair and might be eliminated by apoptosis, thus controlling germinal center size. Our study also has implications for the understanding of immune system development and the sources (and repair) of potentially genome-damaging DNA DSBs. Specifically, our findings indicate that the same mechanisms that introduce developmentally programmed DSBs can carry an inherent and simultaneous risk for the genome at large. This suggests that homologous recombination is important not only for normal lymphocyte development 17 but also for the prevention of lymphoid pathologies such as immunodeficiency or cancer.
METhODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/natureimmunology/.
Note: Supplementary information is available on the Nature Immunology website.
